Under the terms of the agreement,
Oregovomab is a murine monoclonal antibody and a first-in-class anti-CA125 immunotherapy drug candidate. It is being tested in combination with carboplatin and paclitaxel for patients with advanced ovarian cancer. Oregovomab has obtained Orphan Drug Designations from the
'Ovarian cancer is ranked as the eighth most common cancer in women globally[1] and the first-line treatment for this disease has not changed for many years. We have been actively expanding our oncology portfolio through R&D and in-licensing, in order to address unmet medical needs in different types of cancer and bring renewed hope to cancer patients in the MENA region,' said
About Oregovomab
Oregovomab is a murine monoclonal antibody direct to the tumour-associated antigen CA125 that stimulates a host cytotoxic immune response against tumour cells expressing CA 125, a biomarker commonly found in ovarian cancer (OC). In a randomized Phase II clinical trial, oregovomab demonstrated a significant improvement in progression-free and overall survival in advanced OC treatment when administered simultaneously with first-line chemotherapy. Oregovomab yielded a median progression-free survival of 41.8 months compared with 12.2 months with standard chemotherapy (HR, 0.46, P=0.0027). This promising schedule is currently investigated in a phase III trial.
Contact:
Tel: +44 (0) 20 7399 2760
Fax: +44 (0) 20 7399 2761
(C) 2023 Electronic News Publishing, source